News
ETON
12.23
-9.65%
-1.31
Weekly Report: what happened at ETON last week (1125-1129)?
Weekly Report · 5h ago
Eton Pharmaceuticals Price Target Raised to $15.00/Share From $11.00 by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Reiterates Buy on Eton Pharmaceuticals, Raises Price Target to $15
Benzinga · 6d ago
Eton Pharmaceuticals price target raised to $15 from $11 at H.C. Wainwright
TipRanks · 6d ago
ETON PHARMACEUTICALS, INC. <ETON.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $15 FROM $11
Reuters · 6d ago
Eton Pharma - Small Cap That's Climbing
Barchart · 6d ago
Eton Pharmaceuticals Acquires U.S. Rights to Amglidia® for Neonatal Diabetes Treatment Following EMA Approval
Barchart · 11/25 16:16
Craig-Hallum Sticks to Their Buy Rating for Eton Pharmaceuticals (ETON)
TipRanks · 11/25 14:56
Eton Acquires U.S. Rights To Amglidia For Neonatal Diabetes Treatment, Plans NDA Submission In 2026
NASDAQ · 11/25 12:25
Eton Pharmaceuticals acquires U.S. rights to Amglidia from AMMTeK
TipRanks · 11/25 11:55
*Eton Pharmaceuticals Acquires U.S. Rights to Amglidia From AMMTeK; Drug for Treating Neonatal Diabetes Mellitus >ETON
Dow Jones · 11/25 11:53
Eton Pharmaceuticals Has Acquired The Us Rights To Amglidia (Glyburide Oral Suspension, Known As Glibenclamide In Europe) For Neonatal Diabetes Mellitus From AMMTeK, Potential US Marketing Application Submission Expected In 2026
Benzinga · 11/25 11:52
*Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
Dow Jones · 11/25 11:51
ETON PHARMACEUTICALS INC - PLANS FDA MEETING IN Q1 2025, NDA SUBMISSION IN 2026
Reuters · 11/25 11:50
Weekly Report: what happened at ETON last week (1118-1122)?
Weekly Report · 11/25 11:23
What Makes Eton Pharmaceuticals (ETON) a Good Fit for 'Trend Investing'
NASDAQ · 11/18 13:50
Weekly Report: what happened at ETON last week (1111-1115)?
Weekly Report · 11/18 11:20
Friday Sector Laggards: Biotechnology, Drugs
NASDAQ · 11/15 17:15
Analyst Expectations For Eton Pharmaceuticals's Future
Benzinga · 11/13 14:00
Eton Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Dow Jones · 11/13 13:58
More
Webull provides a variety of real-time ETON stock news. You can receive the latest news about Eton Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About ETON
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company's commercial rare disease products include ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ET-400 is a patented formulation of liquid hydrocortisone. It has United States rights to Amglidia (glyburide oral suspension, known as glibenclamide in Europe) for the treatment of neonatal diabetes mellitus.